Myoblast transfer in heart failure.
In conclusion, myoblast transfer has now reached a stage where large randomized trials such as the one we are initiating (300 patients) are mandatory to thoroughly assess the efficacy of the procedure. It is important that the design of these studies complies with the stringent methodologic guidelines commonly used in drug trials, as this is the only means of accurately assessing whether and to what extent skeletal myoblast transfer can really impact the outcome of patients with advanced left-ventricular ischemic dysfunction.
Menasché
Philippe
P
Department of Cardiovascular Surgery, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, Paris 75018, France. ccv-bloc.sec3@bch.ap-hop-paris.fr
D017690:Cell Transplantation / Q000379:methods; D005260:Female; D005602:France; D006084:Graft Rejection; D006085:Graft Survival; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D006801:Humans; D008297:Male; D032448:Myoblasts, Skeletal / Q000637:transplantation*; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D016019:Survival Analysis